Additional Links & References
- Yellow Fever Disease and Vaccine Information
- Yellow Fever Vaccine Requirements and Recommendations, by Country
- Authorized U.S. Yellow Fever Vaccine Centers
- Yellow Fever Vaccine Information Statement (VIS) [PDF - 2 pages]
- General Information about Yellow Fever Vaccine
- Yellow Fever Vaccine Recommendations of the Advisory Committee on Immunization Practices
The 2010 recommendations include new information on the epidemiology of YF, the safety profile of the vaccine, and health regulations related to the vaccine
- How Health Care Providers Can Become Certified to Administer Yellow Fever Vaccine
- Reporting Adverse Events Following Vaccination (Vaccine Adverse Events Reporting System)
- Special Testing for Selected Patients with Serious Adverse Events Potentially Related to Yellow Fever Vaccination
Barwick R. History of thymoma and yellow fever vaccination. Lancet. 2004;364(9438):936.
Cavalcanti DP, Salomao MA, Lopez-Camelo J, et al. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health. 2007;12(7):833–7.
CDC. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(RR-7):1–27.
CDC. Adverse events associated with 17D-derived yellow fever vaccination—United States, 2001–2002. MMWR Morb Mortal Wkly Rep. 2002;51(44):989–93.
Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg. 2007;101(10):967–71.
Jentes ES. Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622-32.
Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077–82.
McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine. 2007;25(10):1727–34.
Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34(10):1369–78.
Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-Vax) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):553–41.
Monath TP, Teuwen D, Cetron MS. Yellow fever vaccine. In: Plotkin S, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia: W.B. Saunders; 2008. p. 959–1055.
Muñoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med. 2008;15(3):202–5.
Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993;87(3):337–9.
Nishioka Sde A, Nunes-Araujo FRF, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case–control study. Trop Med Int Health. 1998;3(1):29–33.
Suzano CE, Amaral E, Sato HK, et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine. 2006;24(9):1421–6.
World Health Organization. Yellow fever vaccine: WHO position paper. Wkly Epidemiol Rec. 2003;40:349–60.
World Health Organization. International Health Regulations. 2005. Geneva. [cited 2008 Jun 9]. Available from: http://www.who.int/csr/ihr/en/index.html .